<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>07</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Fluctuation of Disease Severity and Quality of Life Applying Intralymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis</title>
    <FirstPage>149</FirstPage>
    <LastPage>157</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Khoshkhui</LastName>
        <affiliation locale="en_US">Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Farahzad</FirstName>
        <LastName>Jabbari</LastName>
        <affiliation locale="en_US">Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Fateme</FirstName>
        <LastName>Shafiee Zargar</LastName>
        <affiliation locale="en_US">Department of Radiology, Qaem Hospital, Faculty of Medicine, Mashhad University  of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Nasrin</FirstName>
        <LastName>Motavalli Haghi</LastName>
        <affiliation locale="en_US">Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Nazila</FirstName>
        <LastName>Ariaee</LastName>
        <affiliation locale="en_US">Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>06</Month>
        <Day>07</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>17</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Allergen-specific immunotherapy is the only disease-modifying treatment for IgE-mediated allergic disorders. Intra lymphatic immunotherapy (ILIT) is an efficacious and time-saving alternative to subcutaneous immunotherapy (SCIT). This study aimed to evaluate the effects and safety of ILIT in patients with moderate to severe allergic rhinitis.&#xA0;
In this clinical trial, patients between 18 and 65 years old with moderate to severe allergic rhinitis were enrolled. They received monthly intra-lymphatic inguinal injections of an active allergen (1000 SQ-U Salsola kali pollen). Their clinical symptoms were assessed before and four weeks after treatments. The clinical signs were also evaluated during two consecutive pollination seasons and the following non-pollination season in April.
No moderate or severe reactions were recorded following ILIT treatment. Lymph node enlargement, angioedema/urticaria, and local itching were seen instantly after injection. Patients who received ILIT experienced a significant clinical improvement in self-recorded seasonal allergic symptoms after the treatments, compared to themselves before ILIT. Furthermore, their quality of life significantly improved.
This study suggests ILIT with Salsola-pollen extract may decrease symptoms of allergic rhinitis. It was safe and did not cause any crucial complications.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3852</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3852/2055</pdf_url>
  </Article>
</Articles>
